Results of Crohn’s Disease
Clinical Trial in March 2016
QBECO SSI Clinical Trial for Ulcerative Colitis
A new clinical trial for ulcerative colitis is now underway.Read More
QBECO SSI Treatment
QBECO SSI is derived from components of inactivated E. coli.Read More
Qu Biologics Site Specific Immunomodulators
Dr. Hal Gunn talks about Site Specific Immunomodulators (SSIs), investigational new treatments for IBD. Dr. Gunn talks about Qu Biologics’ research of immune system dysfunction and how SSIs, which are derived from inactivated bacterial components, may stimulate an innate immune response in the GI tract to reverse the underlying chronic bacterial infection/dysbiosis related to IBD.
Crohn’s Disease Clinical Trial Panel Discussion
Gastroenterologist Dr. Brian Bressler, Qu Biologics’ Founder Dr. Hal Gunn and Chief Medical Officer Dr. Simon Sutcliffe answer questions from gastroenterologists about the Phase 1/2 Crohn’s disease clinical trial.
Qu Crohn’s Trial Participant Information
Dr. Hal Gunn explains what people can expect from Qu Biologics’ Crohn’s disease clinical trial. He describes the treatment history and safety profile, patient visits and treatment administration.